scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1039494278 |
P356 | DOI | 10.1038/SREP06031 |
P932 | PMC publication ID | 4129416 |
P698 | PubMed publication ID | 25112436 |
P5875 | ResearchGate publication ID | 264745868 |
P2093 | author name string | Jun Zeng | |
Li Liu | |||
Yong Xia | |||
Qian Lei | |||
Yuquan Wei | |||
Shuang Zhang | |||
Xuejiao Song | |||
Guobo Li | |||
Hongjun Lin | |||
Luoting Yu | |||
Nana Meng | |||
Youzhi Xu | |||
Tinghong Ye | |||
Yongxia Zhu | |||
Yinglan Zhao | |||
Deliang Li | |||
Senyi Deng | |||
Youli Pan | |||
P2860 | cites work | Hallmarks of Cancer: The Next Generation | Q22252312 |
Crystal structure at 1.7 A resolution of VEGF in complex with domain 2 of the Flt-1 receptor | Q24311900 | ||
Targeting HIF-1 for cancer therapy | Q27860504 | ||
Tumor angiogenesis: therapeutic implications | Q27860595 | ||
Stages of embryonic development of the zebrafish | Q27860947 | ||
High frequency of mutations of the PIK3CA gene in human cancers | Q28131776 | ||
Ursolic acid inhibits STAT3 activation pathway leading to suppression of proliferation and chemosensitization of human multiple myeloma cells | Q28248642 | ||
AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer | Q28251373 | ||
Dietary compound isoliquiritigenin inhibits breast cancer neoangiogenesis via VEGF/VEGFR-2 signaling pathway | Q28385231 | ||
Anti-cancer activity of an osthole derivative, NBM-T-BMX-OS01: targeting vascular endothelial growth factor receptor signaling and angiogenesis | Q28535457 | ||
The anthelmintic drug niclosamide induces apoptosis, impairs metastasis and reduces immunosuppressive cells in breast cancer model | Q28538542 | ||
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism | Q29547302 | ||
The STATs of cancer--new molecular targets come of age | Q29614601 | ||
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis | Q29617585 | ||
Automated, quantitative screening assay for antiangiogenic compounds using transgenic zebrafish | Q33308472 | ||
Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro study | Q33495790 | ||
Sorafenib induces growth arrest and apoptosis of human glioblastoma cells through the dephosphorylation of signal transducers and activators of transcription 3 | Q33780701 | ||
Celastrol suppresses angiogenesis-mediated tumor growth through inhibition of AKT/mammalian target of rapamycin pathway | Q33787400 | ||
Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. | Q52507969 | ||
Utilization of distinct signaling pathways by receptors for vascular endothelial cell growth factor and other mitogens in the induction of endothelial cell proliferation | Q73441800 | ||
A highly sensitive model for quantification of in vivo tumor angiogenesis induced by alginate-encapsulated tumor cells | Q73677814 | ||
Transplacental carcinogenesis by stilbestrol | Q95784569 | ||
Targeting mTOR signaling for cancer therapy | Q34220084 | ||
Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay. | Q34355711 | ||
An overview of small-molecule inhibitors of VEGFR signaling | Q34611616 | ||
Role of Akt signaling in vascular homeostasis and angiogenesis | Q34712853 | ||
Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: implications for tumor angiogenesis | Q34729610 | ||
EdU, a new thymidine analogue for labelling proliferating cells in the nervous system | Q34876083 | ||
VEGF and the quest for tumour angiogenesis factors | Q34932327 | ||
Angiogenesis assays: a critical overview | Q35036728 | ||
Kisspeptin-10, a KISS1-derived decapeptide, inhibits tumor angiogenesis by suppressing Sp1-mediated VEGF expression and FAK/Rho GTPase activation | Q35622038 | ||
Targeting the PI3K/Akt/mTOR pathway--beyond rapalogs | Q35640098 | ||
Targeting Stat3 in cancer therapy | Q36147972 | ||
Inactivation of PTEN is associated with increased angiogenesis and VEGF overexpression in gastric cancer | Q36178164 | ||
Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy | Q36278239 | ||
Vascular endothelial growth factor (VEGF)-Receptor2: its biological functions, major signaling pathway, and specific ligand VEGF-E. | Q36489757 | ||
Hypoxia-inducible factors: central regulators of the tumor phenotype | Q36701590 | ||
Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions. | Q37435425 | ||
The VEGF/Rho GTPase signalling pathway: a promising target for anti-angiogenic/anti-invasion therapy. | Q37832021 | ||
Identification of the residues in the extracellular region of KDR important for interaction with vascular endothelial growth factor and neutralizing anti-KDR antibodies | Q38312556 | ||
Inhibition of STAT3 signaling pathway by nitidine chloride suppressed the angiogenesis and growth of human gastric cancer. | Q39421427 | ||
SKLB610: a novel potential inhibitor of vascular endothelial growth factor receptor tyrosine kinases inhibits angiogenesis and tumor growth in vivo | Q39521060 | ||
SKLB1002, a novel potent inhibitor of VEGF receptor 2 signaling, inhibits angiogenesis and tumor growth in vivo | Q39534138 | ||
The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity | Q40023447 | ||
Inhibition of cell proliferation and in vitro markers of angiogenesis by indole-3-carbinol, a major indole metabolite present in cruciferous vegetables | Q40406706 | ||
STAT3 is a potential modulator of HIF-1-mediated VEGF expression in human renal carcinoma cells | Q40416582 | ||
Bleeding complications of antiangiogenic therapy: pathogenetic mechanisms and clinical impact | Q43077944 | ||
ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. | Q44106085 | ||
In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. | Q44285254 | ||
Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene | Q45857630 | ||
P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
P6216 | copyright status | copyrighted | Q50423863 |
P407 | language of work or name | English | Q1860 |
P921 | main subject | angiogenesis inhibitor | Q574834 |
P304 | page(s) | 6031 | |
P577 | publication date | 2014-08-12 | |
P1433 | published in | Scientific Reports | Q2261792 |
P1476 | title | YLT192, a novel, orally active bioavailable inhibitor of VEGFR2 signaling with potent antiangiogenic activity and antitumor efficacy in preclinical models | |
P478 | volume | 4 |
Q91863172 | Alkaloid extract of Corydalis yanhusuo inhibits angiogenesis via targeting vascular endothelial growth factor receptor signaling |
Q38757723 | Antiangiogenesis and vascular disrupting agents in cancer: circumventing resistance and augmenting their therapeutic utility |
Q90400032 | Antipsychotic Drug Trifluoperazine Suppresses Colorectal Cancer by Inducing G0/G1 Arrest and Apoptosis |
Q38286128 | Conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting tyrosine kinase inhibitor-based therapy |
Q33614936 | Disruption of Angiogenesis by Anthocyanin-Rich Extracts of Hibiscus sabdariffa |
Q36772187 | Gamabufotalin, a major derivative of bufadienolide, inhibits VEGF-induced angiogenesis by suppressing VEGFR-2 signaling pathway. |
Q45755977 | Integrated in silico and experimental methods revealed that Arctigenin inhibited angiogenesis and HCT116 cell migration and invasion through regulating the H1F4A and Wnt/β-catenin pathway. |
Q86552947 | Niclosamide inhibits the inflammatory and angiogenic activation of human umbilical vein endothelial cells |
Q36528249 | Nifuroxazide exerts potent anti-tumor and anti-metastasis activity in melanoma |
Q35274726 | Nifuroxazide induces apoptosis and impairs pulmonary metastasis in breast cancer model |
Q64072900 | Repositioning antipsychotic fluphenazine hydrochloride for treating triple negative breast cancer with brain metastases and lung metastases |
Q35983858 | Salinomycin exerts anti-angiogenic and anti-tumorigenic activities by inhibiting vascular endothelial growth factor receptor 2-mediated angiogenesis |
Q64987622 | The enhanced antitumour response of pimozide combined with the IDO inhibitor L‑MT in melanoma. |
Q37520154 | The novel VEGF receptor 2 inhibitor YLL545 inhibits angiogenesis and growth in breast cancer |
Q38558371 | The promise of zebrafish as a chemical screening tool in cancer therapy |
Q47898529 | Tumor-secreted anterior gradient-2 binds to VEGF and FGF2 and enhances their activities by promoting their homodimerization. |
Q38833891 | Utilizing Zebrafish to Identify Anti-(Lymph)Angiogenic Compounds for Cancer Treatment: Promise and Future Challenges |
Q40715107 | Vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitors: development and validation of predictive 3-D QSAR models through extensive ligand- and structure-based approaches |
Q47586776 | miR-1273g-3p participates in acute glucose fluctuation-induced autophagy, dysfunction, and proliferation attenuation in human umbilical vein endothelial cells |
Search more.